The evidence emphasizes that the inflammatory response mediated by COX-2 activation is a key pathological component of depression, and the use of COX-2 as a therapeutic target will become a new strategy for the prevention and treatment of depression in the future. The gene discussed is PTGS2; the disease is major depressive disorder.